|
MXPA02011079A
(es)
|
2000-05-11 |
2004-08-19 |
Consejo Superior Investigacion |
Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
|
|
EP1586318A1
(en)
*
|
2004-04-05 |
2005-10-19 |
Neuropharma S.A.U. |
Thiadiazolidinones as GSK-3 inhibitors
|
|
WO2006045581A1
(en)
*
|
2004-10-21 |
2006-05-04 |
Neuropharma, S.A. |
The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
|
|
ES2258406B1
(es)
*
|
2005-02-10 |
2007-12-01 |
Neuropharma, S.A. |
Uso de compuestos heterociclicos como agentes neurogenicos.
|
|
EP1749523A1
(en)
*
|
2005-07-29 |
2007-02-07 |
Neuropharma, S.A. |
GSK-3 inhibitors
|
|
US9180118B2
(en)
*
|
2006-07-18 |
2015-11-10 |
University Of Rochester |
Thiadiazolidinone derivatives
|
|
WO2008012031A2
(en)
*
|
2006-07-25 |
2008-01-31 |
Universität Bern |
Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
|
|
JP2010500300A
(ja)
|
2006-08-08 |
2010-01-07 |
サノフィ−アベンティス |
アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
|
|
AU2007312165A1
(en)
|
2006-10-21 |
2008-04-24 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
|
|
KR100837785B1
(ko)
*
|
2007-01-17 |
2008-06-13 |
한국화학연구원 |
1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
|
|
KR100829468B1
(ko)
*
|
2007-01-17 |
2008-05-16 |
한국화학연구원 |
신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
EP2242745A1
(de)
*
|
2008-02-07 |
2010-10-27 |
Sanofi-Aventis |
Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
EP2177510A1
(en)
|
2008-10-17 |
2010-04-21 |
Universität des Saarlandes |
Allosteric protein kinase modulators
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
MX2012001729A
(es)
|
2009-08-26 |
2012-06-13 |
Sanofi Sa |
Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2011151359A1
(en)
*
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
CA2810954A1
(en)
|
2010-09-27 |
2012-04-05 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
WO2012065065A1
(en)
*
|
2010-11-12 |
2012-05-18 |
Follica, Inc. |
Methods and compositions for modulating hair growth, wound healing and scar revision
|
|
EP2648676A4
(en)
|
2010-12-06 |
2016-05-04 |
Follica Inc |
METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012149335A2
(en)
*
|
2011-04-28 |
2012-11-01 |
Richard Neubig |
Small molecule inhibitors of rgs proteins
|
|
EP2527323A1
(en)
|
2011-05-24 |
2012-11-28 |
Noscira, S.A. |
Urea carbonyl disulfide derivatives and their therapeutic uses
|
|
WO2012170657A1
(en)
*
|
2011-06-07 |
2012-12-13 |
Georgetown University |
Targeting gsk-3beta for the treatment of parkinson's disease
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
ES2632428T3
(es)
|
2012-02-24 |
2017-09-13 |
Asd Therapeutics Partners Llc |
Nuevas tiadiazolidinadionas como inhibidores de GSK-3
|
|
RU2509155C1
(ru)
*
|
2012-10-25 |
2014-03-10 |
Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук |
Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
|
|
CN103992313A
(zh)
*
|
2013-02-18 |
2014-08-20 |
江苏欧威医药有限公司 |
1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
|
|
CN103992312A
(zh)
*
|
2013-02-18 |
2014-08-20 |
江苏欧威医药有限公司 |
1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
|
|
WO2015075051A1
(en)
|
2013-11-19 |
2015-05-28 |
Universitaet Des Saarlandes |
Allosteric inhibitors of atypical protein kinases c
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
CN106794175B
(zh)
|
2014-06-12 |
2020-06-09 |
西达-赛奈医疗中心 |
用于治疗癌症的组合物
|
|
CN107151235B
(zh)
*
|
2016-03-04 |
2019-12-13 |
上海市计划生育科学研究所 |
噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
|
|
US10751329B2
(en)
*
|
2016-03-10 |
2020-08-25 |
Alma Mater Studiorum—Universitádi Bologna |
Treatment of CDKL5 disorders with GSK3β inhibitor tideglusib
|
|
GB201617820D0
(en)
*
|
2016-10-21 |
2016-12-07 |
King S College London |
Dental treatment
|
|
WO2018226721A1
(en)
*
|
2017-06-06 |
2018-12-13 |
The J. David Gladstone Institutes |
Compositions and methods for reactivating latent immunodeficiency virus using a gsk-3 inhibitor
|
|
KR102919209B1
(ko)
|
2018-08-10 |
2026-01-28 |
다이아핀 테라퓨틱스, 엘엘씨 |
트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
|
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
|
CN113827592B
(zh)
*
|
2020-06-24 |
2024-06-18 |
中国科学院上海药物研究所 |
一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
|
|
JP2024508732A
(ja)
*
|
2021-02-11 |
2024-02-28 |
ベンカ リサーチ，インコーポレイティド |
不整脈原性心筋症を治療するための組成物および方法
|
|
US20240173304A1
(en)
|
2021-02-24 |
2024-05-30 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of tideglusib and process for preparation thereof
|
|
EP4340832A1
(en)
|
2021-05-21 |
2024-03-27 |
Amo Pharma Ltd. |
Method of treating rna repeat mediated diseases with rna repeat binding compound
|
|
EP4094760A1
(en)
|
2021-05-24 |
2022-11-30 |
Consejo Superior De Investigaciones Científicas |
Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
|
|
CN115197167B
(zh)
*
|
2022-07-22 |
2023-07-28 |
中国药科大学 |
1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
|
|
CN117986202B
(zh)
*
|
2024-04-03 |
2024-06-14 |
中国药科大学 |
具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用
|